Axa
IMNM icon

Axa’s Immunome IMNM Stock Holding History

Axa’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-179,519
Closed -$1.67M – 559
2025
Q2 		$1.67M Buy
179,519
+287
+0.2% +$2.35K ﹤0.01% 803
2025
Q1 		$1.21M Sell
179,232
-226
-0.1% -$2.17K ﹤0.01% 819
2024
Q4 		$1.91M Sell
179,458
-283
-0.2% -$3.42K 0.01% 763
2024
Q3 		$2.63M Buy
179,741
+53
+0% +$753 0.01% 689
2024
Q2 		$2.17M Buy
+179,688
New +$2.81M 0.01% 735

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Axa's IMNM Position: Q3 2025 in Review

Axa sold out of Immunome (IMNM) in Q3 2025, closing a stake of 179,519 shares — an estimated $1.67M sold.

Axa first reported a position in IMNM in Q2 2024 and held it in 5 quarters. The position peaked at $2.63M in Q3 2024. 153 funds tracked by Wall St. Rank hold IMNM as of Q3 2025.

  • Axa reported no remaining Immunome position as of Q3 2025 after selling out during the quarter.
  • Axa sold 179,519 Immunome shares in Q3 2025, an estimated $1.67M.
  • Axa first reported a position in Immunome in Q2 2024 and held it in 5 quarters.
  • Axa's Immunome position peaked at $2.63M in Q3 2024.
  • 153 funds tracked by Wall St. Rank held Immunome as of Q3 2025.

Based on Axa's 13F filing for Q3 2025, filed 14 Nov 2025.